Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
This gene encodes a member of the cysteine-aspartic acid protease (caspase) family. Sequential activation of caspases plays a central role in the execution-phase of cell apoptosis. Caspases exist as inactive proenzymes composed of a prodomain, a large protease subunit, and a small protease subunit. Activation of caspases requires proteolytic processing at conserved internal aspartic residues to generate a heterodimeric enzyme consisting of the large and small subunits. This protein is involved in the programmed cell death induced by Fas and various apoptotic stimuli. The N-terminal FADD-like death effector domain of this protein suggests that it may interact with Fas-interacting protein FADD. This protein was detected in the insoluble fraction of the affected brain region from Huntington disease patients but not in those from normal controls, which implicated the role in neurodegenerative diseases. Many alternatively spliced transcript variants encoding different isoforms have been described, although not all variants have had their full-length sequences determined.
Loading...
| CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
| CAR-CQ0109 | Anti-CASP8 (CBXC-3111) h(41BB-CD3ζ) CAR, pCDCAR1 | Human, Primate | CBXC-3111 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-CQ0110 | Anti-CASP8 (CBXC-0083) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBXC-0083 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-CQ0111 | Anti-CASP8 (XHM58) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | XHM58 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-CQ0112 | Anti-CASP8 (CBXC-0084) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBXC-0084 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-CQ0113 | Anti-CASP8 (CBXC-2270) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBXC-2270 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-CQ0114 | Anti-CASP8 (CBXC-0082) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBXC-0082 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-CQ0115 | Anti-CASP8 (CBXC-1334) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBXC-1334 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-CQ0116 | Anti-CASP8 (FLICE 4-1-20) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | FLICE 4-1-20 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-CQ3533 | Anti-CASP8 (CBXC-3111) h(CD28-CD3ζ) CAR, pCDCAR1 | Human, Primate | CBXC-3111 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-CQ3534 | Anti-CASP8 (CBXC-0083) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | CBXC-0083 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-CQ3535 | Anti-CASP8 (XHM58) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | XHM58 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-CQ3536 | Anti-CASP8 (CBXC-0084) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | CBXC-0084 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-CQ3537 | Anti-CASP8 (CBXC-2270) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | CBXC-2270 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-CQ3538 | Anti-CASP8 (CBXC-0082) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | CBXC-0082 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-CQ3539 | Anti-CASP8 (CBXC-1334) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | CBXC-1334 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-CQ3540 | Anti-CASP8 (FLICE 4-1-20) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | FLICE 4-1-20 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY2661 | Anti-CASP8 (CBFYC-0853) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBFYC-0853 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY2662 | Anti-CASP8 (CBFYC-0854) h(41BB-CD3ζ) CAR, pCDCAR1 | Mouse | CBFYC-0854 | Rat | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY2663 | Anti-CASP8 (CBFYC-0855) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBFYC-0855 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY2664 | Anti-CASP8 (CBFYC-0856) h(41BB-CD3ζ) CAR, pCDCAR1 | Human, Mouse, Rat | CBFYC-0856 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell |
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
